Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2016)
16 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 15, 2016
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 15 November 2016
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Key Financial Details
Key Financial Details For personal use only ASX Code Market Share Price1 Capitalisation ANR $54.4 million $1.10 Current Cash2 Ordinary Shares Share Price $13.8 million 49,413,236 up 162% since IPO 1. As at 14 November 2016 2. Appendix 4E ‐ 30 June 2016 3
Slide 4: ANR Share Price Chart
ANR Share Price Chart For personal use only 4
Slide 5: Detach: Oral therapeutics for gastrointestinal disease in livestock and humans
Oral therapeutics for gastrointestinal disease in livestock and humans For personal use only Detach™ • Natural, safe, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases, including diarrhoea • Meets the need to reduce the use of antibiotics in animal production • Unlike ant
Slide 6: Need to combat antimicrobial resistance
Need to combat antimicrobial resistance For personal use only resistance to antibiotics ‘….the greatest and most urgent global risk’ General Assembly of the United Nations 2016 Antibiotic resistance driven by the overuse of antibiotics • 10 million: the number of people who will die every year due t
Slide 7: Lead Indication – Pigs
Lead Indication – Pigs Diarrhoea affects hundreds of millions of piglets born each year For personal use only Millions of piglets weaned per year 20% more piglets die before weaning due to health issues 7
Slide 8: Market Opportunity is clear
Market Opportunity is clear DetachTM addresses a major need – the livestock industry need effective For personal use only • alternatives to antibiotics to prevent diarrhoea • Global animal antibiotic market valued at ~ $4.6 billion in 20141. Production animals 70%. Pigs lead by market share of 25%.
Slide 9: FY16 – Key Achievements
FY16 – Key Achievements For personal use only Milestone Partnering Zoetis have exclusive worldwide right (excl. AU/NZ) to evaluate Detach™ for veterinary use in livestock Animal safety trials Detach™ proven safe in piglets even when administered at 5x and more frequent than the recommended dose Subm
Slide 10: Detach: Poised for swift market entry
Detach™ Poised for swift market entry Commercially validated, supported by demand For personal use only • A clear path to market: Launch in 2017 • Proven efficacy on commercial pig farms (therapeutic claims) • Proven safety (active ingredient is GRAS) Current 50 kg scale • Manufacturing complete at
Slide 11: Human Applications
For personal use only Human Applications There are 4 billion episodes of diarrhoea in the world annually. Diarrhoea is the second cause of death in children under 5 years, and the leading cause of malnutrition. 11
Slide 12: Detach from Pigs to People
Detach™ from Pigs to People For personal use only 12
Slide 13: Anatara technology – for humans
Anatara technology – for humans For personal use only • DetachTM technology to treat human gastrointestinal conditions, such as: • Inflammatory bowel disease and • Irritable bowel syndrome • Traveller’s Diarrhoea • Significant unmet need not addressed by current products 13
Slide 14: Human gastro related disorders/disease
Human gastro related disorders/disease For personal use only 14
Slide 15: Detach for Humans
DetachTM for Humans For personal use only Status • Mode of action clearly understood, based on decades of research • Pre-clinical efficacy database is very strong due to leverage of Detach™ data from pig studies • Proof of concept in several animal models • Confirmed efficacy in rabbit models with h
Slide 16: Thank you
Thank you For personal use only Anatara’s naturally derived substances offer a safe but effective alternative to antibiotics for gastrointestinal diseases and the Company is uniquely positioned to fulfil a currently unmet need in the huge, global animal health market. Dr Mel Bridges, CEO & Chairman,
Anatara Lifesciences — Shareholder Meeting (November 2016) on 6ix